论文部分内容阅读
对 2 4例Ⅱb～Ⅲb乳腺癌患者进行术前新辅助化疗 ,并与 3 6例术后化疗患者作随访对照。结果 :术前新辅助化疗组总体有效率 (CR +PR) 75 % ,区域淋巴结缓解有效率 (CR +PR) 60 %。化疗前后肿瘤平均体积缩小 5 6.83 % (P <0 .0 5 )。 2 4例术后随访 2～ 6年 ,死亡 2例 ,局部复发 1例 ,无瘤生存 2 1例。对照组 3 6例 ,死亡 8例 ,局部复发 2例 ,骨转移 3例 ,肺胸膜转移 2例 ,锁骨上转移 1例 ,无瘤生存 2 0例。无瘤生存率两组有显著差异 (P <0 .0 5 )。提示术前新辅助化疗能使局部晚期乳腺癌原发灶缩小 ,肿瘤临床降期 ,减少肿瘤的远处转移 ,提高总生存率及无瘤生存率
Preoperative neoadjuvant chemotherapy was performed on 24 patients with stage IIb-IIIb breast cancer, and 36 cases were followed up with 36 cases of postoperative chemotherapy. Results: The preoperative neoadjuvant chemotherapy group had a total effective rate (CR + PR) of 75% and regional lymph node response rate (CR + PR) of 60%. Before and after chemotherapy, the average tumor volume was reduced by 5 6.83% (P <0.05). Twenty-four patients were followed up for 2 to 6 years, 2 died, 1 had local recurrence, and 21 survived without tumor. There were 36 cases in the control group, 8 cases died, 2 cases local recurrence, 3 cases bone metastasis, 2 cases pulmonary pleurodesis, 1 case supraclavicular metastasis and 20 cases without tumor. The tumor-free survival rate was significantly different between the two groups (P <0.05). It is suggested that neoadjuvant chemotherapy can reduce the primary tumor of locally advanced breast cancer, clinically reduce the tumor, reduce distant metastasis of tumor, and improve the overall survival and tumor-free survival